Hans Moebius
Technik-/Wissenschafts-/F&E-Leiter bei Exciva GmbH
Vermögen: 175 645 $ am 30.04.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Mark Litton | M | 56 | 5 Jahre | |
| Kelly Romano | F | 62 | 4 Jahre | |
| Grant Pickering | M | 56 | 2 Jahre | |
| Joseph Edelman | M | 67 | 4 Jahre | |
| James Johnson | M | 67 | 4 Jahre | |
| Barbara Kosacz | F | 66 | 3 Jahre | |
| Mark Worthington | M | 58 | 3 Jahre | |
| Michael Panzara | M | 57 | 2 Jahre | |
| Robert Renninger | M | - | 4 Jahre | |
| Rachel Lenington | F | 51 | 3 Jahre | |
| Andrew Gengos | M | 59 | 1 Jahre | |
| François Conquet | M | - |
Exciva GmbH
 Exciva GmbH Miscellaneous Commercial ServicesCommercial Services Exciva GmbH is a clinical stage biopharmaceutical company located in Heidelberg, Germany. Exciva is focused on delivering an innovative treatment to address symptoms of Alzheimer's patients. The German company's main product, Deraphan©, is a combination of two clinically validated products that act on well-documented pharmacological pathways in the field of neuropsychiatry. The symptoms that Exciva aims to address are the Behavioral and Psychological Symptoms in Demented patients (BPSD), which appear in clusters with aging and are particularly prevalent in Alzheimer's disease. The company was founded by Hans Moebius and the CEOs are Bespalov Anton and François Conquet. | - |
| Bespalov Anton | M | - |
Exciva GmbH
Exciva GmbH Miscellaneous Commercial ServicesCommercial Services Exciva GmbH is a clinical stage biopharmaceutical company located in Heidelberg, Germany. Exciva is focused on delivering an innovative treatment to address symptoms of Alzheimer's patients. The German company's main product, Deraphan©, is a combination of two clinically validated products that act on well-documented pharmacological pathways in the field of neuropsychiatry. The symptoms that Exciva aims to address are the Behavioral and Psychological Symptoms in Demented patients (BPSD), which appear in clusters with aging and are particularly prevalent in Alzheimer's disease. The company was founded by Hans Moebius and the CEOs are Bespalov Anton and François Conquet. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Leen Kawas | M | 38 | 10 Jahre | |
| Tadataka Yamada | M | 77 | 2 Jahre | |
| Glenna Mileson | F | 66 | 8 Jahre | |
| George Bickerstaff | M | 68 | - | |
| Josh Pan | M | - | 7 Jahre | |
| Xue Hua | M | - | 7 Jahre | |
| Samantha Haeberlein | M | - |
Rodin Therapeutics, Inc.
 Rodin Therapeutics, Inc. BiotechnologyHealth Technology Rodin Therapeutics, Inc. develops first in class therapeutics for cognitive disorders. The company was founded by Bruce Booth in 2013 and is headquartered in Cambridge, MA. | - |
| Setsuko Hashimoto | M | 70 |
Ruprecht-Karls-Universität Heidelberg
| 3 Jahre |
| Helmut Kraft | M | 64 |
Ruprecht-Karls-Universität Heidelberg
| 5 Jahre |
| Norbert Steiner | M | 70 |
Ruprecht-Karls-Universität Heidelberg
| 3 Jahre |
| Bernd Eisele | M | - |
Ruprecht-Karls-Universität Heidelberg
| 3 Jahre |
| Roland Kaplan | M | - |
Ruprecht-Karls-Universität Heidelberg
| 4 Jahre |
| Klaus Dembowsky | M | - |
Ruprecht-Karls-Universität Heidelberg
| 3 Jahre |
| Bernhard R. M. Ehmer | M | 69 |
Ruprecht-Karls-Universität Heidelberg
| 6 Jahre |
| Utz-Hellmuth Felcht | M | 76 |
Technische Universität Kaiserslautern
| 3 Jahre |
| Peter Gruss | M | 74 |
Ruprecht-Karls-Universität Heidelberg
| 4 Jahre |
| Luis Miguel Cardozo Goytizolo | M | 73 |
Ruprecht-Karls-Universität Heidelberg
| 3 Jahre |
| Joachim Müller | M | 65 |
Ruprecht-Karls-Universität Heidelberg
| 4 Jahre |
| Richard Kayne | M | 79 | - | |
| Lawrence E. Chun | M | - | 7 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 20 | 60,61% |
| Deutschland | 13 | 39,39% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Hans Moebius
- Persönliches Netzwerk
